Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2013

01.03.2013

Harm reduction and cessation efforts and interest in cessation resources among survivors of smoking-related cancers

verfasst von: Carla J. Berg, Matthew J. Carpenter, Bianca Jardin, Jamie S. Ostroff

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite the well-established risks associated with persistent smoking, many cancer survivors who were active smokers at the time of cancer diagnosis continue to smoke. In order to guide the development of tobacco cessation interventions for cancer survivors, a better understanding is needed regarding post-diagnosis quitting efforts. Thus, we examined quitting and reduction efforts and interest in cessation resources among cancer survivors who self-identified as current smokers at the time of diagnosis.

Methods

We conducted analyses of survey participants (n = 54) who were current smokers at the time of cancer diagnosis and were continued smokers at the time of assessment. We also conducted semi-structured interviews (n = 21) among a subset of those who either continued to smoke or quit smoking post-cancer diagnosis.

Results

Among our survey participants, 22.2 % had ever used behavioral cessation resources and 66.7 % had use pharmacotherapy, while 62.8 % had interest in future use of behavioral cessation resources and 75.0 % had interest in pharmacotherapy. The majority reported some quitting efforts including making quit attempts, using cessation medications, and reducing their daily cigarette consumption. Semi-structured interview data revealed various strategies used to aid in smoking reduction and cessation as well as variability in preferences for cessation resources.

Conclusions

Cancer patients who smoke following diagnosis often engage in smoking reduction and cessation-related behaviors, which may reflect their motivation to reduce their smoking-related risks. They also report high interest in cessation resources. Thus, it is important to explore the acceptability and effectiveness of different cessation intervention components among this group.

Implications for Cancer Survivors

Cancer survivors who smoke demonstrate actions toward harm reduction and cessation. They should inquire about potential resources that might facilitate their efforts among their healthcare providers and enlist support and advice from others around them to bolster their efforts.
Literatur
2.
Zurück zum Zitat Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15–25.PubMedCrossRef Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15–25.PubMedCrossRef
3.
Zurück zum Zitat Centers for Disease Control and Prevention. Surveillance of Demographic Characteristics and Health Behaviors Among Adult Cancer Survivors—Behavioral Risk Factor Surveillance System, United States, 2009. MMWR Morb Mortal Wkly Rep. 2012;61:1–23. Centers for Disease Control and Prevention. Surveillance of Demographic Characteristics and Health Behaviors Among Adult Cancer Survivors—Behavioral Risk Factor Surveillance System, United States, 2009. MMWR Morb Mortal Wkly Rep. 2012;61:1–23.
4.
Zurück zum Zitat Cooley ME, Lundin R, Murray L. Smoking cessation interventions in cancer care: opportunities for oncology nurses and nurse scientists. Annu Rev Nurs Res. 2009;27:243–72.PubMedCrossRef Cooley ME, Lundin R, Murray L. Smoking cessation interventions in cancer care: opportunities for oncology nurses and nurse scientists. Annu Rev Nurs Res. 2009;27:243–72.PubMedCrossRef
5.
Zurück zum Zitat Underwood JM, Townsend JS, Tai E, White A, Davis SP, Fairley TL. Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. J Cancer Surviv. 2012; doi: 10.1007/s11764-012-0230-1 Underwood JM, Townsend JS, Tai E, White A, Davis SP, Fairley TL. Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. J Cancer Surviv. 2012; doi: 10.​1007/​s11764-012-0230-1
6.
Zurück zum Zitat Des Rochers C, Dische S, Saunders MI. The problem of cigarette smoking in radiotherapy for cancer in the head and neck. Clin Oncol (R Coll Radiol). 1992;4:214–6.CrossRef Des Rochers C, Dische S, Saunders MI. The problem of cigarette smoking in radiotherapy for cancer in the head and neck. Clin Oncol (R Coll Radiol). 1992;4:214–6.CrossRef
7.
Zurück zum Zitat Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340:b5569.PubMedCrossRef Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340:b5569.PubMedCrossRef
8.
Zurück zum Zitat Browman GP, Wong G, Hodson I, Sathya J, Russell R, McAlpine L, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med. 1993;328:159–63.PubMedCrossRef Browman GP, Wong G, Hodson I, Sathya J, Russell R, McAlpine L, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med. 1993;328:159–63.PubMedCrossRef
9.
Zurück zum Zitat Stevens MH, Gardner JW, Parkin JL, Johnson LP. Head and neck cancer survival and life-style change. Arch Otolaryngol. 1983;109:746–9.PubMedCrossRef Stevens MH, Gardner JW, Parkin JL, Johnson LP. Head and neck cancer survival and life-style change. Arch Otolaryngol. 1983;109:746–9.PubMedCrossRef
10.
Zurück zum Zitat Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck Jr BE, Ihde DC, et al. Smoking abstinence and small cell lung cancer survival. An association. JAMA J Am Med Assoc. 1980;244:2175–9.CrossRef Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck Jr BE, Ihde DC, et al. Smoking abstinence and small cell lung cancer survival. An association. JAMA J Am Med Assoc. 1980;244:2175–9.CrossRef
11.
Zurück zum Zitat Mason DP, Subramanian S, Nowicki ER, Grab JD, Murthy SC, Rice TW, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database Study. Ann Thorac Surg. 2009;88:362–71.PubMedCrossRef Mason DP, Subramanian S, Nowicki ER, Grab JD, Murthy SC, Rice TW, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database Study. Ann Thorac Surg. 2009;88:362–71.PubMedCrossRef
12.
Zurück zum Zitat Chelghoum Y, Danaïla C, Belhabri A, Charrin C, Le QH, Michallet M, et al. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol. 2002;13:1621–7.PubMedCrossRef Chelghoum Y, Danaïla C, Belhabri A, Charrin C, Le QH, Michallet M, et al. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol. 2002;13:1621–7.PubMedCrossRef
13.
Zurück zum Zitat Karim AB, Snow GB, Siek HT, Njo KH. The quality of voice in patients irradiated for laryngeal carcinoma. Cancer. 1983;51:47–9.PubMedCrossRef Karim AB, Snow GB, Siek HT, Njo KH. The quality of voice in patients irradiated for laryngeal carcinoma. Cancer. 1983;51:47–9.PubMedCrossRef
14.
Zurück zum Zitat Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. Br J Radiol. 1990;63:554–6.PubMedCrossRef Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. Br J Radiol. 1990;63:554–6.PubMedCrossRef
15.
Zurück zum Zitat Tyc VL, Hudson MM, Hinds P, Elliott V, Kibby MY. Tobacco use among pediatric cancer patients: recommendations for developing clinical smoking interventions. J Clin Oncol. 1997;15:2194–204.PubMed Tyc VL, Hudson MM, Hinds P, Elliott V, Kibby MY. Tobacco use among pediatric cancer patients: recommendations for developing clinical smoking interventions. J Clin Oncol. 1997;15:2194–204.PubMed
16.
Zurück zum Zitat Gritz ER, Kristeller J, Burns DM. Treating nicotine addiction in high-risk groups and patients with medical co-morbidity. In: Orleans CT, Slade J, editors. Nicotine addiction: principles and management. New York: Oxford University Press; 1993. p. 279–309. Gritz ER, Kristeller J, Burns DM. Treating nicotine addiction in high-risk groups and patients with medical co-morbidity. In: Orleans CT, Slade J, editors. Nicotine addiction: principles and management. New York: Oxford University Press; 1993. p. 279–309.
19.
Zurück zum Zitat Wynder EL, Mushinski MH, Spivak JC. Tobacco and alcohol consumption in relation to the development of multiple primary cancers. Cancer. 1977;40:1872–8.PubMedCrossRef Wynder EL, Mushinski MH, Spivak JC. Tobacco and alcohol consumption in relation to the development of multiple primary cancers. Cancer. 1977;40:1872–8.PubMedCrossRef
20.
Zurück zum Zitat Day GL, Blot WJ, Shore RE, McLaughlin JK, Austin DF, Greenberg RS, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst. 1994;86:131–7.PubMedCrossRef Day GL, Blot WJ, Shore RE, McLaughlin JK, Austin DF, Greenberg RS, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst. 1994;86:131–7.PubMedCrossRef
21.
Zurück zum Zitat Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Contr. 2003;14:131–8.CrossRef Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Contr. 2003;14:131–8.CrossRef
22.
Zurück zum Zitat Blum A. Cancer prevention: preventing tobacco-related cancers. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven Publishers; 1997. p. 545–57. Blum A. Cancer prevention: preventing tobacco-related cancers. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven Publishers; 1997. p. 545–57.
23.
Zurück zum Zitat Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006;98:441–50.PubMedCrossRef Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006;98:441–50.PubMedCrossRef
24.
Zurück zum Zitat Cox LS, Africano NL, Tercyak KP, Taylor KL. Nicotine dependence treatment for patients with cancer. Cancer. 2003;98:632–44.PubMedCrossRef Cox LS, Africano NL, Tercyak KP, Taylor KL. Nicotine dependence treatment for patients with cancer. Cancer. 2003;98:632–44.PubMedCrossRef
25.
Zurück zum Zitat Richardson GE, Tucker MA, Venzon DJ, Linnoila RI, Phelps R, Phares JC, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med. 1993;119:383–90.PubMed Richardson GE, Tucker MA, Venzon DJ, Linnoila RI, Phelps R, Phares JC, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med. 1993;119:383–90.PubMed
26.
Zurück zum Zitat Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst. 1997;89:1782–8.PubMedCrossRef Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst. 1997;89:1782–8.PubMedCrossRef
27.
Zurück zum Zitat Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst. 1998;90:1335–45.PubMedCrossRef Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst. 1998;90:1335–45.PubMedCrossRef
28.
Zurück zum Zitat Kawahara M, Ushijima S, Kamimori T, Kodama N, Ogawara M, Matsui K, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer. 1998;78:409–12.PubMedCrossRef Kawahara M, Ushijima S, Kamimori T, Kodama N, Ogawara M, Matsui K, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer. 1998;78:409–12.PubMedCrossRef
29.
Zurück zum Zitat American Society for Clinical Oncology. Tobacco cessation and quality cancer care. J Oncol Pract. 2009;5:2–5.CrossRef American Society for Clinical Oncology. Tobacco cessation and quality cancer care. J Oncol Pract. 2009;5:2–5.CrossRef
30.
Zurück zum Zitat Gritz ER, Carr CR, Rapkin DA, Chang C, Beumer J, Ward PH. A smoking cessation intervention for head and neck cancer patients: trial design, patient accrual, and characteristics. Cancer Epidemiol Biomarkers Prev. 1991;1:67–73.PubMed Gritz ER, Carr CR, Rapkin DA, Chang C, Beumer J, Ward PH. A smoking cessation intervention for head and neck cancer patients: trial design, patient accrual, and characteristics. Cancer Epidemiol Biomarkers Prev. 1991;1:67–73.PubMed
31.
Zurück zum Zitat Gritz ER, Fingeret MC, Vidrine DJ, Lazev AB, Mehta NV, Reece GP. Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer. 2006;106:17–27.PubMedCrossRef Gritz ER, Fingeret MC, Vidrine DJ, Lazev AB, Mehta NV, Reece GP. Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer. 2006;106:17–27.PubMedCrossRef
32.
Zurück zum Zitat Stanislaw AE, Wewers ME. A smoking cessation intervention with hospitalized surgical cancer patients: a pilot study. Cancer Nurs. 1994;17:81–6.PubMedCrossRef Stanislaw AE, Wewers ME. A smoking cessation intervention with hospitalized surgical cancer patients: a pilot study. Cancer Nurs. 1994;17:81–6.PubMedCrossRef
33.
Zurück zum Zitat Griebel B, Wewers ME, Baker CA. The effectiveness of a nurse-managed minimal smoking-cessation intervention among hospitalized patients with cancer. Oncol Nurs Forum. 1998;25:897–902.PubMed Griebel B, Wewers ME, Baker CA. The effectiveness of a nurse-managed minimal smoking-cessation intervention among hospitalized patients with cancer. Oncol Nurs Forum. 1998;25:897–902.PubMed
34.
Zurück zum Zitat Wewers ME, Bowen JM, Stanislaw AE, Desimone VB. A nurse-delivered smoking cessation intervention among hospitalized postoperative patients—influence of a smoking-related diagnosis: a pilot study. Heart Lung. 1994;23:151–6.PubMed Wewers ME, Bowen JM, Stanislaw AE, Desimone VB. A nurse-delivered smoking cessation intervention among hospitalized postoperative patients—influence of a smoking-related diagnosis: a pilot study. Heart Lung. 1994;23:151–6.PubMed
35.
Zurück zum Zitat Schnoll RA, James C, Malstrom M, Rothman RL, Wang H, Babb J, et al. Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med. 2003;25:214–22.PubMedCrossRef Schnoll RA, James C, Malstrom M, Rothman RL, Wang H, Babb J, et al. Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med. 2003;25:214–22.PubMedCrossRef
36.
Zurück zum Zitat Shields PG. Tobacco smoking, harm reduction, and biomarkers. J Natl Cancer Inst. 2002;94:1435–44.PubMedCrossRef Shields PG. Tobacco smoking, harm reduction, and biomarkers. J Natl Cancer Inst. 2002;94:1435–44.PubMedCrossRef
37.
Zurück zum Zitat Godtfredsen N, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA J Am Med Assoc. 2005;294:1505–10.CrossRef Godtfredsen N, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA J Am Med Assoc. 2005;294:1505–10.CrossRef
38.
Zurück zum Zitat Institute of Medicine. Clearing the smoke: assessing the science base for tobacco harm reduction. Institute of Medicine, Committee to Assess the Science Base for Tobacco Harm Reduction, Board on Health Promotion and Disease Prevention: Washington, DC; 2001. Institute of Medicine. Clearing the smoke: assessing the science base for tobacco harm reduction. Institute of Medicine, Committee to Assess the Science Base for Tobacco Harm Reduction, Board on Health Promotion and Disease Prevention: Washington, DC; 2001.
39.
Zurück zum Zitat Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res. 2006;8:739–49.PubMedCrossRef Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res. 2006;8:739–49.PubMedCrossRef
40.
Zurück zum Zitat Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data (BRFSS). 2008. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data (BRFSS). 2008.
41.
Zurück zum Zitat Substance Abuse, Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings, 2009. Rockvillle: Office of Applied Studies; 2009. Substance Abuse, Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings, 2009. Rockvillle: Office of Applied Studies; 2009.
42.
Zurück zum Zitat Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119–27.PubMedCrossRef Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119–27.PubMedCrossRef
43.
Zurück zum Zitat Biener L, Abrams DB. The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10:360–5.PubMedCrossRef Biener L, Abrams DB. The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10:360–5.PubMedCrossRef
44.
Zurück zum Zitat Maibach EW, Maxfield A, Ladin K, Slater M. Translating health psychology into effective health communication. J Health Psychol. 1996;1:261–7.PubMedCrossRef Maibach EW, Maxfield A, Ladin K, Slater M. Translating health psychology into effective health communication. J Health Psychol. 1996;1:261–7.PubMedCrossRef
45.
Zurück zum Zitat California Department of Health and Human Services. Tobacco Control Section, California Tobacco Survey: 1999. Jolla: Cancer Prevention and Control Unit; 1999. California Department of Health and Human Services. Tobacco Control Section, California Tobacco Survey: 1999. Jolla: Cancer Prevention and Control Unit; 1999.
46.
Zurück zum Zitat Prochaska JO, DiClemente CC. Self change processes, self-efficacy and decisional balance across five stages of smoking cessation. Advances in Cancer Control—1983–1984. New York: Alan R. Liss; pp. 131–140. Prochaska JO, DiClemente CC. Self change processes, self-efficacy and decisional balance across five stages of smoking cessation. Advances in Cancer Control—1983–1984. New York: Alan R. Liss; pp. 131–140.
47.
Zurück zum Zitat Berg CJ, Thomas AN, Mertens AC, Schauer GL, Pinsker EA, Ahluwalia JS, et al. Correlates of continued smoking versus cessation among survivors of smoking-related cancers. Psychooncology. 2012; doi: 10.1002/pon.3077 Berg CJ, Thomas AN, Mertens AC, Schauer GL, Pinsker EA, Ahluwalia JS, et al. Correlates of continued smoking versus cessation among survivors of smoking-related cancers. Psychooncology. 2012; doi: 10.​1002/​pon.​3077
48.
Zurück zum Zitat Morgan DL, Krueger RA. The Focus Group Kit. Thousand Oaks: Sage; 1998. Morgan DL, Krueger RA. The Focus Group Kit. Thousand Oaks: Sage; 1998.
49.
Zurück zum Zitat Patton M. Qualitative Research and Evaluation Methods. 3rd ed. Thousand Oaks: Sage; 2002. Patton M. Qualitative Research and Evaluation Methods. 3rd ed. Thousand Oaks: Sage; 2002.
50.
Zurück zum Zitat Miles MB, Huberman AM. Qualitative data analysis: an expanded sourcebook. 2nd ed. Thousand Oaks: Sage; 1994. Miles MB, Huberman AM. Qualitative data analysis: an expanded sourcebook. 2nd ed. Thousand Oaks: Sage; 1994.
51.
Zurück zum Zitat Centers for Disease Control and Prevention, Tobacco use among adults—United States 2005. MMWR Morb Mortal Wkly Rep. 2006;55:1145–8. Centers for Disease Control and Prevention, Tobacco use among adults—United States 2005. MMWR Morb Mortal Wkly Rep. 2006;55:1145–8.
52.
Zurück zum Zitat Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34:102–11.PubMedCrossRef Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34:102–11.PubMedCrossRef
53.
Zurück zum Zitat Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Individual differences in adoption of treatment for smoking cessation: demographic and smoking history characteristics. Drug Alcohol Depend. 2008;93:121–31.PubMedCrossRef Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Individual differences in adoption of treatment for smoking cessation: demographic and smoking history characteristics. Drug Alcohol Depend. 2008;93:121–31.PubMedCrossRef
54.
Zurück zum Zitat Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One. 2009;4:e7524.PubMedCrossRef Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One. 2009;4:e7524.PubMedCrossRef
55.
Zurück zum Zitat National Cancer Institute. Risks Associated With Smoking Cigarettes With Low Machine-Measured Yields of Tar and Nicotine. Smoking and Tobacco Control Monograph 13. Bethesda: National Cancer Institute; 2001. National Cancer Institute. Risks Associated With Smoking Cigarettes With Low Machine-Measured Yields of Tar and Nicotine. Smoking and Tobacco Control Monograph 13. Bethesda: National Cancer Institute; 2001.
57.
Zurück zum Zitat Augustine A, Harris RE, Wynder EL. Compensation as a risk factor for lung cancer in smokers who switch from nonfilter to filter cigarettes. Am J Public Health. 1989;79:188–91.PubMedCrossRef Augustine A, Harris RE, Wynder EL. Compensation as a risk factor for lung cancer in smokers who switch from nonfilter to filter cigarettes. Am J Public Health. 1989;79:188–91.PubMedCrossRef
58.
Zurück zum Zitat Stellman SD, Muscat JE, Hoffmann D, Wynder EL. Impact of filter cigarette smoking on lung cancer histology. Prev Med. 1997;26:451–6.PubMedCrossRef Stellman SD, Muscat JE, Hoffmann D, Wynder EL. Impact of filter cigarette smoking on lung cancer histology. Prev Med. 1997;26:451–6.PubMedCrossRef
59.
Zurück zum Zitat Hoffmann D, Hoffmann I. The changing cigarette, 1950–1995. J Toxicol Environ Health. 1997;50:307–64.PubMedCrossRef Hoffmann D, Hoffmann I. The changing cigarette, 1950–1995. J Toxicol Environ Health. 1997;50:307–64.PubMedCrossRef
60.
Zurück zum Zitat National Cancer Institute, Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine, in Smoking and tobacco control [Monograph 13]2002: Washington, DC. National Cancer Institute, Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine, in Smoking and tobacco control [Monograph 13]2002: Washington, DC.
61.
Zurück zum Zitat Wennike P, Danielsson T, Landfeldt B, Westin A, Tønnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003;98:1395–402.PubMedCrossRef Wennike P, Danielsson T, Landfeldt B, Westin A, Tønnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003;98:1395–402.PubMedCrossRef
62.
Zurück zum Zitat Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav. 2011;36:764–8.PubMedCrossRef Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav. 2011;36:764–8.PubMedCrossRef
Metadaten
Titel
Harm reduction and cessation efforts and interest in cessation resources among survivors of smoking-related cancers
verfasst von
Carla J. Berg
Matthew J. Carpenter
Bianca Jardin
Jamie S. Ostroff
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2013
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-012-0243-9

Weitere Artikel der Ausgabe 1/2013

Journal of Cancer Survivorship 1/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.